Is NEU or CBT a better buy right now?

Based on our latest analysis, CBT is currently the stronger investment candidate based on our comprehensive scoring model.

Does NEU or CBT have better growth?

Our analysis compares revenue and earnings growth. Check the 'Growth' section above to see which company is expanding faster. Typically, the stock with higher revenue growth rates is considered the better growth stock.

Which stock is cheaper: NEU or CBT?

We compare P/E ratios and other valuation metrics in the 'Valuation' section. The stock with the lower P/E ratio is generally considered 'cheaper' relative to its earnings, though growth prospects must also be considered.

Which is the better buy right now, NEU or CBT?

As of Aug 15, 2026, CBT scores higher in our model: NEU has an AI score of 31.7 versus 64.7 for CBT. NEU is currently in a Markup technical phase and CBT is in a Neutral phase. Consider both scores and phases alongside your own risk tolerance.

What technical phase are NEU and CBT in?

NEU is in a Markup phase (Hold / add on dips) with an RSI of 68.4. CBT is in a Neutral phase (Hold) with an RSI of 45.3.

NEU vs CBT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 15, 2026

NEU

31.7

AI Score

CBT Wins

CBT

64.7

AI Score

Investment Advisor Scores

NEU

32score

Recommendation

SELL

View Full Analysis

CBT

65score

Recommendation

BUY

View Full Analysis

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric	NEU	CBT	Winner
Revenue	1.42B	2.73B	CBT
Net Income	251.82M	147.00M	NEU
Gross Margin	32.7%	22.1%	NEU
Net Margin	17.8%	5.4%	NEU
Operating Income	306.89M	356.00M	CBT
ROE	13.7%	9.2%	NEU
ROA	7.0%	3.7%	NEU
Total Assets	3.62B	3.98B	CBT
Cash	93.60M	250.00M	CBT
Debt/Equity	0.47	0.52	NEU
Current Ratio	2.25	1.47	NEU
Free Cash Flow	234.42M	126.00M	NEU

Relative Price Performance (Last 90 Days)

NEU 1M: +21.7% · 3M: +30.1% CBT 1M: -4.4% · 3M: +8.7%

Current Technical Phase

NEU

Markup

Hold / add on dips

Price above SMA50, rising 50-day trend (7.0% over 20 days), RSI 68

RSI (14): 68.4 · Price: $937.34

CBT

Neutral

Hold

Mixed signals - no dominant trend phase, RSI 45

RSI (14): 45.3 · Price: $85.19

Fundamentals Snapshot

Metric	NEU	CBT
Market Cap	—	—
Forward P/E	22.5	12.2
Trailing P/E	20.0	23.9
Revenue (TTM)	—	—
Revenue Growth	0.1%	0.1%
Gross Margin	0.3%	0.2%
Operating Margin	0.2%	0.1%
EPS	46.29	3.56
Dividend Yield	0.01%	0.02%

Frequently Asked Questions

Based on our detailed analysis, CBT is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.

Related Analysis

NEU

CBT

Data derived from SEC EDGAR filings and Tradestie proprietary analysis. Last updated: Aug 15, 2026 11:07 UTC. Refresh Data

Tradestie